Xencor: Plamotamab NHL Data Leads To RA Program Advancement
Portfolio Pulse from
Xencor is advancing its Plamotamab program with promising Phase 1 data for Non-Hodgkin's Lymphoma, and plans to initiate a Phase 1b/2a study for Rheumatoid Arthritis in 2025. Additionally, Xencor is developing XmAb657 for autoimmune disorders, with a Phase 1 trial expected in the second half of 2025.
November 22, 2024 | 7:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xencor's Plamotamab shows promising Phase 1 data for Non-Hodgkin's Lymphoma, with further studies planned for Rheumatoid Arthritis. XmAb657 is also in development for autoimmune disorders.
The positive Phase 1 data for Plamotamab in NHL and the planned studies for RA and XmAb657 indicate potential growth and innovation in Xencor's pipeline, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100